Subhashis Banerjee

3.6k total citations · 5 hit papers
62 papers, 2.6k citations indexed

About

Subhashis Banerjee is a scholar working on Immunology, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Subhashis Banerjee has authored 62 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Immunology, 20 papers in Oncology and 17 papers in Pathology and Forensic Medicine. Recurrent topics in Subhashis Banerjee's work include Psoriasis: Treatment and Pathogenesis (46 papers), Cytokine Signaling Pathways and Interactions (19 papers) and Autoimmune Bullous Skin Diseases (13 papers). Subhashis Banerjee is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (46 papers), Cytokine Signaling Pathways and Interactions (19 papers) and Autoimmune Bullous Skin Diseases (13 papers). Subhashis Banerjee collaborates with scholars based in United States, Germany and Japan. Subhashis Banerjee's co-authors include Gregory S. Cameron, Daniel Braun, Emily Edson‐Heredia, Linda Li, Claus Zachariae, Craig L. Leonardi, Robert Matheson, Diamant Thaçi, Kim Papp and Akimichi Morita and has published in prestigious journals such as New England Journal of Medicine, The FASEB Journal and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Subhashis Banerjee

60 papers receiving 2.5k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis

2012 741 citations Daniel Braun, Subhashis Banerjee et al. profile →
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial

2022 219 citations April W. Armstrong, Melinda Gooderham et al. Journal of the American Academy of Dermatology profile →
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial

2022 173 citations Bruce Strober, Diamant Thaçi et al. Journal of the American Academy of Dermatology profile →
Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double‐Blind, Placebo‐Controlled Trial

2022 139 citations Ian M. Catlett, Subhashis Banerjee et al. profile →
Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis

2022 134 citations Philip J. Mease, Atul Deodhar et al. Annals of the Rheumatic Diseases profile →

Peers

Countries citing papers authored by Subhashis Banerjee

Since Specialization

Citations

This map shows the geographic impact of Subhashis Banerjee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Subhashis Banerjee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Subhashis Banerjee more than expected).

Fields of papers citing papers by Subhashis Banerjee

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Subhashis Banerjee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Subhashis Banerjee. The network helps show where Subhashis Banerjee may publish in the future.

Co-authorship network of co-authors of Subhashis Banerjee

This figure shows the co-authorship network connecting the top 25 collaborators of Subhashis Banerjee. A scholar is included among the top collaborators of Subhashis Banerjee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Subhashis Banerjee. Subhashis Banerjee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Deucravacitinib in plaque psoriasis: Four‐year safety and efficacy results from the Phase 3 POETYK PSO‐1, PSO‐2 and long‐term extension trials 2025 ·Journal of the European Academy of Dermatology and Venereology ·April W. Armstrong, Mark Lebwohl, Richard B. Warren, Howard Sofen, Akimichi Morita, C. Paul, Kim Papp, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Georgene Schroeder, Subhashis Banerjee, Diamant Thaçi, Bruce Strober	8
2	Deucravacitinib in plaque psoriasis: Safety and efficacy through 3 years in Japanese patients in the phase 3 POETYK PSO ‐1, PSO ‐4, and LTE trials 2025 ·The Journal of Dermatology ·Akimichi Morita, Shinichi Imafuku, Yayoi Tada, Yukari Okubo, (unknown), Katsuki Tsuritani, Subhashis Banerjee, (unknown), (unknown), Mamitaro Ohtsuki	1
3	Deucravacitinib in moderate‐to‐severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO‐1 and PSO‐2) 2024 ·Journal of the European Academy of Dermatology and Venereology ·Bruce Strober, Andrew Blauvelt, Richard B. Warren, Kim Papp, April W. Armstrong, Kenneth B. Gordon, Akimichi Morita, Andrew Alexis, Mark Lebwohl, Peter Foley, Renata M. Kisa, Elizabeth Colston, Tao Wang, Subhashis Banerjee, Diamant Thaçi	27
4	Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials 2024 ·British Journal of Dermatology ·Mark Lebwohl, Richard B. Warren, Howard Sofen, Shinichi Imafuku, C. Paul, Jacek C. Szepietowski, Lynda Spelman, Thierry Passeron, (unknown), Andrew Napoli, (unknown), (unknown), Subhashis Banerjee, Diamant Thaçi, Andrew Blauvelt	35
5	Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials 2024 ·Dermatology and Therapy ·April W. Armstrong, Matthias Augustin, Jennifer L. Beaumont, (unknown), Stacie Hudgens, Kenneth B. Gordon, (unknown), Brandon Becker, (unknown), (unknown), Subhashis Banerjee, Kim Papp	3
6	Deucravacitinib, a selective, TYK2 inhibitor, in psoriatic arthritis: achievement of minimal disease activity components in a phase 2 trial 2024 ·Lara D. Veeken ·Arthur Kavanaugh, Laura C. Coates, Philip J. Mease, Miroslawa Nowak, (unknown), Thomas Lehman, Subhashis Banerjee, Joseph F. Merola	3
7	Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials 2024 ·Journal of Dermatological Treatment ·Neil J. Korman, Richard B. Warren, Jerry Bagel, April W. Armstrong, Melinda Gooderham, Bruce Strober, Diamant Thaçi, Akimichi Morita, Shinichi Imafuku, Peter Foley, Howard Sofen, Min Zheng, (unknown), Renata M. Kisa, Subhashis Banerjee, Andrew Blauvelt	1
8	Deucravacitinib in Plaque Psoriasis: Laboratory Parameters Through 4 Years of Treatment in the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials 2024 ·SKIN The Journal of Cutaneous Medicine ·Neil J. Korman, Thierry Passeron, Yukari Okubo, Jerry Bagel, (unknown), Lynda Spelman, Kevin Winthrop, (unknown), (unknown), Subhashis Banerjee, Diamant Thaçi, Mona Shahriari, Linda Stein Gold	2
9	Deucravacitinib in Plaque Psoriasis: 4-Year Safety and Efficacy Results From the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials 2024 ·SKIN The Journal of Cutaneous Medicine ·April W. Armstrong, Mark Lebwohl, Richard B. Warren, Howard Sofen, (unknown), (unknown), Mamitaro Ohtsuki, Lynda Spelman, Thierry Passeron, Kim Papp, (unknown), (unknown), (unknown), (unknown), (unknown), Subhashis Banerjee, Bruce Strober, Diamant Thaçi, Andrew Blauvelt	2
10	Pharmacodynamic Response to Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in a Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled Psoriasis Trial 2024 ·Dermatology and Therapy ·Ian M. Catlett, Lu Gao, Yanhua Hu, Subhashis Banerjee, James G. Krueger	1
11	Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: evaluation of lipid parameters in the phase 3 POETYK PSO-1 and PSO-2 trials 2023 ·SKIN The Journal of Cutaneous Medicine ·Mark Lebwohl, Bruce Strober, Misti Linaberry, (unknown), Subhashis Banerjee, Renata M. Kisa, Nehal N. Mehta	1
12	Sustained Remission and Outcomes with Abatacept plus Methotrexate Following Stepwise Dose De-escalation in Patients with Early Rheumatoid Arthritis 2023 ·Rheumatology and Therapy ·Paul Emery, Yoshiya Tanaka, Vivian P. Bykerk, T. Huizinga, Gustavo Citera, Clifton O. Bingham, Subhashis Banerjee, Benjamin P. Soule, Marleen Nys, Seán Connolly, (unknown), (unknown), Robert Wong, Kuan‐Hsiang Gary Huang, R. Fleischmann	6
13	Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two phase 3 randomized trials in plaque psoriasis 2023 ·Journal of the American Academy of Dermatology ·Andrew Blauvelt, Phoebe Rich, Howard Sofen, Bruce Strober, Joseph F. Merola, Mark Lebwohl, Akimichi Morita, Jacek C. Szepietowski, Jo Lambert, (unknown), Elizabeth Colston, (unknown), Subhashis Banerjee, Diamant Thaçi	12
14	Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Absolute PASI Outcomes Over 52 Weeks in the Phase 3 POETYK PSO-1 Trial 2023 ·SKIN The Journal of Cutaneous Medicine ·Mark Lebwohl, Melinda Gooderham, Richard B. Warren, Diamant Thaçi, Peter Foley, Alice B. Gottlieb, (unknown), Renata M. Kisa, Subhashis Banerjee, C.E.M. Griffiths	1
15	Efficacy and safety of the selective TYK2 inhibitor, deucravacitinib, in Japanese patients with moderate to severe plaque psoriasis: Subgroup analysis of a randomized, double‐blind, placebo‐controlled, global phase 3 trial 2023 ·The Journal of Dermatology ·Shinichi Imafuku, Yayoi Tada, (unknown), Subhashis Banerjee, Akimichi Morita, Mamitaro Ohtsuki	22
16	Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis breakdown → 2022 ·Annals of the Rheumatic Diseases ·Philip J. Mease, Atul Deodhar, Désirée van der Heijde, Frank Behrens, Alan Kivitz, Jeffrey Neal, Jonghyeon Kim, Shalabh Singhal, Miroslawa Nowak, Subhashis Banerjee	134
17	Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial breakdown → 2022 ·Journal of the American Academy of Dermatology ·April W. Armstrong, Melinda Gooderham, Richard B. Warren, Kim Papp, Bruce Strober, Diamant Thaçi, Akimichi Morita, Jacek C. Szepietowski, Shinichi Imafuku, (unknown), John Throup, Sudeep Kundu, Steve Schoenfeld, Misti Linaberry, Subhashis Banerjee, Andrew Blauvelt	219
18	Safety of Abatacept Versus Placebo in Rheumatoid Arthritis: Integrated Data Analysis of Nine Clinical Trials 2019 ·ACR Open Rheumatology ·Teresa A. Simon, Benjamin P. Soule, Marc C. Hochberg, Douglas Fleming, A. Torbeyns, Subhashis Banerjee, Maarten Boers	17
19	Efficacy and Safety of a Potent and Highly Selective Oral Tyrosine Kinase 2 Inhibitor, BMS-986165, in Patients with Moderate-to-Severe Plaque Psoriasis: A Phase II, Randomized, Placebo-Controlled Trial 2018 ·Arthritis & Rheumatism ·Kim Papp, Kenneth B. Gordon, Diamant Thaçi, Akimichi Morita, Melinda Gooderham, Peter Foley, Ihab Girgis, Sudeep Kundu, Subhashis Banerjee	1
20	Safety and Efficacy of Open-label Subcutaneous Ixekizumab Treatment for 48 Weeks in a Phase II Study in Biologic-naive and TNF-IR Patients with Rheumatoid Arthritis 2015 ·The Journal of Rheumatology ·Mark C. Genovese, Daniel Braun, J. Erickson, Pierre‐Yves Berclaz, Subhashis Banerjee, Michael Heffernan, Hilde Carlier	30

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact